ARTICLE | Clinical News

SAR164877: Additional Phase II data

July 26, 2010 7:00 AM UTC

Additional data from the double-blind, U.S. Phase II Study 0901 trial in 217 patients showed that the 0.1 and 0.3 mg/kg doses of IV REGN475 significantly reduced mean NRS walking pain scores from baseline to week 8 by 3.4 and 3.3 points, respectively, vs. 2.2 points for placebo (p<0.01 for both). The 0.03 mg/kg dose non-significantly reduced NRS walking pain score by 2.9 points vs. placebo. Additionally, mid- and high-dose REGN475 significantly reduced WOMAC pain scores from baseline to week 8 by 3 and 2.9 points, respectively, vs. 1.9 points for placebo (p<0.01 and p=0.01). Low-dose REGN475 non-significantly reduced WOMAC score by 2.4 points vs. placebo. ...